Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Проблема безопасности применения ацетилсалициловой кислоты в практике кардиолога и терапевта
Проблема безопасности применения ацетилсалициловой кислоты в практике кардиолога и терапевта
Минушкина Л.О. Проблема безопасности применения ацетилсалициловой кислоты в практике кардиолога и терапевта. Consilium Medicum. 2017; 19 (5): 43–46.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Данный обзор посвящен проблемам безопасности терапии ацетилсалициловой кислотой (АСК). АСК является наиболее часто назначаемым антиагрегантным препаратом с максимально широким кругом показаний. В то же время увеличение риска кровотечений существенно осложняет практику назначения антитромботической терапии. В обзоре рассмотрены основные подходы к профилактике осложнений, безопасность разных форм АСК.
Ключевые слова: антиагрегант, вторичная профилактика, безопасность, кровотечения.
Key words: antiaggregant, secondary prevention, safety, hemorrhage.
Ключевые слова: антиагрегант, вторичная профилактика, безопасность, кровотечения.
________________________________________________
Key words: antiaggregant, secondary prevention, safety, hemorrhage.
Полный текст
Список литературы
1. Roffi M, Patrono C, Collet JP et al; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (3): 267–315. DOI: 10.1093/eurheartj/ehv320. PubMed PMID: 26320110
2. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with --segment elevation. Eur Heart J 2012; 33 (20): 2569–619.
3. Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J 2014; 35 (46): 3235–6. DOI: 10.1093/eurheartj/ehu422
4. Mancia G, Fagard R, Narkiewicz K et al; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23 (1): 3–16.
5. Wenger NK. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol 2014; 37 (4): 239–51. 10.1136/bmj.b2584. PubMed PMID: 19584409
6. Kolber M, Sharif N, Marceau R, Szafran O. Family practice patients’ use of acetylsalicylic acid for cardiovascular disease prevention Can Fam Physician 2013; 59: 55–61.
7. Taylor DW, Barnett HJ, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179–84.
8. Woo D, Haverbusch M, Sekar P et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004; 35: 1703–8.
9. Hsu PI, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des 2015; 21 (35): 5049–55.
10. Sørensen HT, Mellemkjaer L, Blot WJ et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95 (9): 2218–24.
11. Yaguchi T, Yokoyama H, Nakamura H et al. Evaluation of the development of gastroduodenal lesions in patients treated with low-dose aspirin or non-steroidal anti-inflammatory drugs. Yakugaku Zasshi 2011; 131 (7): 1085–94.
12. Vaduganathan M, Cannon CP, Cryer BL et al; COGENT Investigators. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med 2016; 129 (9): 1002–5. DOI: 10.1016/j.amjmed.2016.03.042
13. Mo C, Sun G, Lu ML et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21 (17): 5382–92.
14. Chan FK, Ching JY, Suen BY et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144 (3): 528–35.
15. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310 (6983): 827–30.
16. Henry P, Vermillet A, Boval B et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105 (2): 336–44.
17. Jaspers Focks J, Tielemans MM, van Rossum LG et al. Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth Heart J 2014; 22 (3): 107–12.
18. Patrick J, Johnson A, Dillaha L, Pennell AT. Safety and tolerability of extended-release acetylsalicylic acid capsules: a summary of double-blind comparative studies. Future Cardiol 2016; 12 (6): 627–38.
19. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181–91.
20. Endo H, Sakai E, Kato T et al. Small bowel injury in low-dose aspirin users. J Gastroenterol 2015; 50 (4): 378–86.
21. Endo H, Sakai E, Taniguchi L et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc 2014; 80 (5): 826–34.
22. Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011 Jul;46(7-8):803-9
23. Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation 2016; 134 (20): 1579–94.
24. Бурячковская Л.И., Ломакин Н.В., Русанова А.В., Вершинина М.Г. Резистентность к ацетилсалициловой кислоте: причины и следствие. Сердце. 2016; 5: 379–88. / Buriachkovskaia L.I., Lomakin N.V., Rusanova A.V., Vershinina M.G. Rezistentnost' k atsetilsalitsilovoi kislote: prichiny i sledstvie. Serdtse. 2016; 5: 379–88. [in Russian]
25. Bhatt DL, Grosser T, Dong JF et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 2017; 69 (6): 603–12. DOI: 10.1016/j.jacc.2016.11.050
26. Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc 2014; 7: 137–46.
2. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with --segment elevation. Eur Heart J 2012; 33 (20): 2569–619.
3. Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J 2014; 35 (46): 3235–6. DOI: 10.1093/eurheartj/ehu422
4. Mancia G, Fagard R, Narkiewicz K et al; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23 (1): 3–16.
5. Wenger NK. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol 2014; 37 (4): 239–51. 10.1136/bmj.b2584. PubMed PMID: 19584409
6. Kolber M, Sharif N, Marceau R, Szafran O. Family practice patients’ use of acetylsalicylic acid for cardiovascular disease prevention Can Fam Physician 2013; 59: 55–61.
7. Taylor DW, Barnett HJ, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179–84.
8. Woo D, Haverbusch M, Sekar P et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004; 35: 1703–8.
9. Hsu PI, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des 2015; 21 (35): 5049–55.
10. Sørensen HT, Mellemkjaer L, Blot WJ et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95 (9): 2218–24.
11. Yaguchi T, Yokoyama H, Nakamura H et al. Evaluation of the development of gastroduodenal lesions in patients treated with low-dose aspirin or non-steroidal anti-inflammatory drugs. Yakugaku Zasshi 2011; 131 (7): 1085–94.
12. Vaduganathan M, Cannon CP, Cryer BL et al; COGENT Investigators. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med 2016; 129 (9): 1002–5. DOI: 10.1016/j.amjmed.2016.03.042
13. Mo C, Sun G, Lu ML et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21 (17): 5382–92.
14. Chan FK, Ching JY, Suen BY et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144 (3): 528–35.
15. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310 (6983): 827–30.
16. Henry P, Vermillet A, Boval B et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105 (2): 336–44.
17. Jaspers Focks J, Tielemans MM, van Rossum LG et al. Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth Heart J 2014; 22 (3): 107–12.
18. Patrick J, Johnson A, Dillaha L, Pennell AT. Safety and tolerability of extended-release acetylsalicylic acid capsules: a summary of double-blind comparative studies. Future Cardiol 2016; 12 (6): 627–38.
19. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181–91.
20. Endo H, Sakai E, Kato T et al. Small bowel injury in low-dose aspirin users. J Gastroenterol 2015; 50 (4): 378–86.
21. Endo H, Sakai E, Taniguchi L et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc 2014; 80 (5): 826–34.
22. Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011 Jul;46(7-8):803-9
23. Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation 2016; 134 (20): 1579–94.
24. Buriachkovskaia L.I., Lomakin N.V., Rusanova A.V., Vershinina M.G. Rezistentnost' k atsetilsalitsilovoi kislote: prichiny i sledstvie. Serdtse. 2016; 5: 379–88. [in Russian]
25. Bhatt DL, Grosser T, Dong JF et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 2017; 69 (6): 603–12. DOI: 10.1016/j.jacc.2016.11.050
26. Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc 2014; 7: 137–46.
2. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with --segment elevation. Eur Heart J 2012; 33 (20): 2569–619.
3. Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J 2014; 35 (46): 3235–6. DOI: 10.1093/eurheartj/ehu422
4. Mancia G, Fagard R, Narkiewicz K et al; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23 (1): 3–16.
5. Wenger NK. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol 2014; 37 (4): 239–51. 10.1136/bmj.b2584. PubMed PMID: 19584409
6. Kolber M, Sharif N, Marceau R, Szafran O. Family practice patients’ use of acetylsalicylic acid for cardiovascular disease prevention Can Fam Physician 2013; 59: 55–61.
7. Taylor DW, Barnett HJ, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179–84.
8. Woo D, Haverbusch M, Sekar P et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004; 35: 1703–8.
9. Hsu PI, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des 2015; 21 (35): 5049–55.
10. Sørensen HT, Mellemkjaer L, Blot WJ et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95 (9): 2218–24.
11. Yaguchi T, Yokoyama H, Nakamura H et al. Evaluation of the development of gastroduodenal lesions in patients treated with low-dose aspirin or non-steroidal anti-inflammatory drugs. Yakugaku Zasshi 2011; 131 (7): 1085–94.
12. Vaduganathan M, Cannon CP, Cryer BL et al; COGENT Investigators. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med 2016; 129 (9): 1002–5. DOI: 10.1016/j.amjmed.2016.03.042
13. Mo C, Sun G, Lu ML et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21 (17): 5382–92.
14. Chan FK, Ching JY, Suen BY et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144 (3): 528–35.
15. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310 (6983): 827–30.
16. Henry P, Vermillet A, Boval B et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105 (2): 336–44.
17. Jaspers Focks J, Tielemans MM, van Rossum LG et al. Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth Heart J 2014; 22 (3): 107–12.
18. Patrick J, Johnson A, Dillaha L, Pennell AT. Safety and tolerability of extended-release acetylsalicylic acid capsules: a summary of double-blind comparative studies. Future Cardiol 2016; 12 (6): 627–38.
19. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181–91.
20. Endo H, Sakai E, Kato T et al. Small bowel injury in low-dose aspirin users. J Gastroenterol 2015; 50 (4): 378–86.
21. Endo H, Sakai E, Taniguchi L et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc 2014; 80 (5): 826–34.
22. Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011 Jul;46(7-8):803-9
23. Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation 2016; 134 (20): 1579–94.
24. Бурячковская Л.И., Ломакин Н.В., Русанова А.В., Вершинина М.Г. Резистентность к ацетилсалициловой кислоте: причины и следствие. Сердце. 2016; 5: 379–88. / Buriachkovskaia L.I., Lomakin N.V., Rusanova A.V., Vershinina M.G. Rezistentnost' k atsetilsalitsilovoi kislote: prichiny i sledstvie. Serdtse. 2016; 5: 379–88. [in Russian]
25. Bhatt DL, Grosser T, Dong JF et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 2017; 69 (6): 603–12. DOI: 10.1016/j.jacc.2016.11.050
26. Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc 2014; 7: 137–46.
________________________________________________
2. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with --segment elevation. Eur Heart J 2012; 33 (20): 2569–619.
3. Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J 2014; 35 (46): 3235–6. DOI: 10.1093/eurheartj/ehu422
4. Mancia G, Fagard R, Narkiewicz K et al; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23 (1): 3–16.
5. Wenger NK. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol 2014; 37 (4): 239–51. 10.1136/bmj.b2584. PubMed PMID: 19584409
6. Kolber M, Sharif N, Marceau R, Szafran O. Family practice patients’ use of acetylsalicylic acid for cardiovascular disease prevention Can Fam Physician 2013; 59: 55–61.
7. Taylor DW, Barnett HJ, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179–84.
8. Woo D, Haverbusch M, Sekar P et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004; 35: 1703–8.
9. Hsu PI, Tsai TJ. Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. Curr Pharm Des 2015; 21 (35): 5049–55.
10. Sørensen HT, Mellemkjaer L, Blot WJ et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95 (9): 2218–24.
11. Yaguchi T, Yokoyama H, Nakamura H et al. Evaluation of the development of gastroduodenal lesions in patients treated with low-dose aspirin or non-steroidal anti-inflammatory drugs. Yakugaku Zasshi 2011; 131 (7): 1085–94.
12. Vaduganathan M, Cannon CP, Cryer BL et al; COGENT Investigators. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med 2016; 129 (9): 1002–5. DOI: 10.1016/j.amjmed.2016.03.042
13. Mo C, Sun G, Lu ML et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol 2015; 21 (17): 5382–92.
14. Chan FK, Ching JY, Suen BY et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144 (3): 528–35.
15. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310 (6983): 827–30.
16. Henry P, Vermillet A, Boval B et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105 (2): 336–44.
17. Jaspers Focks J, Tielemans MM, van Rossum LG et al. Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin. Neth Heart J 2014; 22 (3): 107–12.
18. Patrick J, Johnson A, Dillaha L, Pennell AT. Safety and tolerability of extended-release acetylsalicylic acid capsules: a summary of double-blind comparative studies. Future Cardiol 2016; 12 (6): 627–38.
19. Takada M, Fujimoto M, Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181–91.
20. Endo H, Sakai E, Kato T et al. Small bowel injury in low-dose aspirin users. J Gastroenterol 2015; 50 (4): 378–86.
21. Endo H, Sakai E, Taniguchi L et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc 2014; 80 (5): 826–34.
22. Hirata Y, Kataoka H, Shimura T et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011 Jul;46(7-8):803-9
23. Capodanno D, Angiolillo DJ. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. Circulation 2016; 134 (20): 1579–94.
24. Buriachkovskaia L.I., Lomakin N.V., Rusanova A.V., Vershinina M.G. Rezistentnost' k atsetilsalitsilovoi kislote: prichiny i sledstvie. Serdtse. 2016; 5: 379–88. [in Russian]
25. Bhatt DL, Grosser T, Dong JF et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol 2017; 69 (6): 603–12. DOI: 10.1016/j.jacc.2016.11.050
26. Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc 2014; 7: 137–46.
Авторы
Л.О.Минушкина
ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ. 121359, Россия, Москва, ул. Маршала Тимошенко, д. 19, стр. 1а
minushkina@mail.ru
Central State Medical Academy of Administration of the President of Russian Federation. 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 19, str. 1a
minushkina@mail.ru
ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РФ. 121359, Россия, Москва, ул. Маршала Тимошенко, д. 19, стр. 1а
minushkina@mail.ru
________________________________________________
Central State Medical Academy of Administration of the President of Russian Federation. 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 19, str. 1a
minushkina@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.